Small Molecule Drug Substance Pandemic Complications
Source: ISR Reports
Over the past two years, ISR has asked respondents to its annual small molecule drug substance benchmarking surveys whether they encountered pandemic related complications with their outsourced manufacturing. The data show it was slightly more common for small molecule API outsourcers to experience COVID-19 related manufacturing complications in 2021 than during 2020. To learn more about small molecule API manufacturers’ performance during the pandemic, follow the link to the Small Molecule API CMO Benchmarking report preview.
access the Infographic!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.
Subscribe to Outsourced Pharma
X
Subscribe to Outsourced Pharma
ISR Reports
This website uses cookies to ensure you get the best experience on our website. Learn more